Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers
- PMID: 36792374
- DOI: 10.1212/WNL.0000000000207199
Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers
Comment on
-
Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.Neurology. 2023 May 23;100(21):1010-1019. doi: 10.1212/WNL.0000000000206891. Epub 2023 Jan 31. Neurology. 2023. PMID: 36720642 Free PMC article.